Background: Background parenchymal enhancement (BPE) on breast magnetic resonance imaging (MRI) could also be related to breast most cancers threat, however earlier research of the affiliation are equivocal and restricted by incomplete blinding of BPE evaluation. On this research, we evaluated the affiliation between BPE and breast most cancers primarily based on totally blinded assessments of BPE within the unaffected breast.
Strategies: The Imaging and Epidemiology (IMAGINE) research is a multicenter breast most cancers case-control research of girls receiving diagnostic, screening, or follow-up breast MRI, recruited from three complete most cancers facilities within the USA. Instances had a primary prognosis of unilateral breast most cancers and controls had no historical past of or present breast most cancers. A single board-certified breast radiologist with 12 years’ expertise, blinded to case-control standing and medical data, assessed the unaffected breast for BPE with out view of the affected breast of circumstances (or the corresponding breast laterality of controls). The affiliation between BPE and breast most cancers was estimated by multivariable logistic regression individually for premenopausal and postmenopausal ladies.
Outcomes: The analytic dataset included 835 circumstances and 963 controls. Adjusting for fibroglandular tissue (breast density), age, race/ethnicity, BMI, parity, household historical past of breast most cancers, BRCA1/BRCA2 mutations, and different confounders, reasonable/marked BPE (vs minimal/delicate BPE) was related to breast most cancers amongst premenopausal ladies. Amongst postmenopausal ladies, delicate/reasonable/marked vs minimal BPE had an analogous, however statistically non-significant, affiliation with breast most cancers.
Conclusions: BPE is related to breast most cancers in premenopausal ladies, and probably postmenopausal ladies, after adjustment for breast density and confounders. Our outcomes counsel that BPE needs to be evaluated alongside breast density for inclusion in fashions predicting breast most cancers threat.
Rhenium N-heterocyclic carbene complexes block development of aggressive cancers by inhibiting FGFR- and SRC-mediated signalling
Background: Platinum-based anticancer medicine have been on the frontline of most cancers remedy for the final 40 years, and are utilized in greater than half of all therapies for various most cancers sorts. Nevertheless, they aren’t universally efficient, and sufferers usually endure extreme uncomfortable side effects due to their lack of mobile selectivity. There’s subsequently a compelling want to research the anticancer exercise of other steel complexes. Right here we describe the potential anticancer exercise of rhenium-based complexes with preclinical efficacy in various kinds of stable malignancies.
Strategies: Kinase profile assay of rhenium complexes. Toxicology research utilizing zebrafish. Evaluation of the expansion of pancreatic most cancers cell line-derived xenografts generated in zebrafish and in mice upon publicity to rhenium compounds.
Outcomes: We describe rhenium complexes which block most cancers proliferation in vitro by inhibiting the signalling cascade induced by FGFR and Src. Initially, we examined the toxicity of rhenium complexes in vivo utilizing a zebrafish mannequin and recognized one compound that shows anticancer exercise with low toxicity even within the excessive micromolar vary. Notably, the rhenium complicated has anticancer exercise in very aggressive cancers corresponding to pancreatic ductal adenocarcinoma and neuroblastoma. We display the potential efficacy of this complicated through a big discount in most cancers development in mouse xenografts.
Conclusions: Our findings present a foundation for the event of rhenium-based chemotherapy brokers with enhanced selectivity and restricted uncomfortable side effects in comparison with commonplace platinum-based medicine.
Association of breast cancer with MRI background parenchymal enhancement: the IMAGINE case-control study
Precision Instruments in Immuno-Oncology: Artificial Gene Circuits for Most cancers Immunotherapy
Engineered mammalian cells for medical functions have gotten a clinically related actuality because of advances in artificial biology that permit enhanced reliability and security of cell-based therapies. Nevertheless, their software continues to be hampered by challenges together with time-consuming design-and-test cycle iterations and prices. For instance, within the discipline of most cancers immunotherapy, CAR-T cells focusing on CD19 have already been clinically authorised to deal with a number of varieties of leukemia, however their use within the context of stable tumors continues to be fairly inefficient, with extra points associated to the sufficient high quality management for medical use. These limitations may be overtaken by revolutionary bioengineering approaches presently in improvement.
Right here we current an outline of latest artificial biology methods for mammalian cell therapies, with a particular concentrate on the genetic engineering enhancements on CAR-T cells, discussing situations for the subsequent era of genetic circuits for most cancers immunotherapy. Targeted ultrasound (FUS) has develop into an necessary non-invasive remedy for stable tumor ablation through thermal results. The cavitation impact induced by FUS is thereby prevented however utilized for lithotripsy, help drug supply and the induction of blood vessel destruction for most cancers remedy. On this research, head and neck most cancers (FaDu), glioblastoma (T98G), and prostate most cancers (PC-3) cells have been uncovered to FUS through the use of an in vitro FUS system adopted by single-dose X-ray radiation remedy (RT) or water tub hyperthermia (HT).
 ELISA Kit) Human Carbohydrate Antigen 72-4 (CA72-4) ELISA Kit |
|
RDR-CA72-4-Hu-48Tests |
Reddot Biotech |
48 Tests |
EUR 500 |
Human Carbohydrate Antigen 72-4 (CA72-4) ELISA Kit |
|
RDR-CA72-4-Hu-96Tests |
Reddot Biotech |
96 Tests |
EUR 692 |
) BSA (Standard Grade) |
|
30-AB70 |
Fitzgerald |
1 kg |
EUR 899 |
|
Description: Standard Grade Bovine Serum Albumin (99% pure) |
, antigen grade) Gastrointestinal Cancer Antigen (CA 19-9), antigen grade |
|
CA1991-N-10 |
Alpha Diagnostics |
10 KU |
EUR 529 |
 Inactivated RuV Grade 4 Antigen |
|
VAng-Lsx0477-1mg |
Creative Biolabs |
1 mg |
EUR 3080 |
|
Description: RuV Grade 4, natural antigen. |
 Antibody) Carbohydrate Antigen 72-4 (CA72-4) Antibody |
|
20-abx102717 |
Abbexa |
-
EUR 398.00
-
EUR 133.00
-
EUR 1107.00
-
EUR 537.00
-
EUR 314.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
|
Carbohydrate Antigen 72-4 (CA72-4) Antibody |
|
abx023799-1mg |
Abbexa |
1 mg |
EUR 1156 |
|
|
Carbohydrate Antigen 72-4 (CA72-4) Antibody |
|
abx023800-1mg |
Abbexa |
1 mg |
EUR 1156 |
|
|
Carbohydrate Antigen 72-4 (CA72-4) Antibody |
|
abx023801-1mg |
Abbexa |
1 mg |
EUR 1156 |
|
|
 Proteinase K, Recombinant, Standard Grade |
|
9250-100 |
Biovision |
|
EUR 104 |
Proteinase K, Recombinant, Standard Grade |
|
9250-10G |
Biovision |
|
EUR 3856 |
Proteinase K, Recombinant, Standard Grade |
|
9250-1G |
Biovision |
|
EUR 457 |
Proteinase K, Recombinant, Standard Grade |
|
9250-500 |
Biovision |
|
EUR 262 |
Proteinase K, Recombinant, Standard Grade |
|
9251-100 |
Biovision |
|
EUR 1055 |
Proteinase K, Recombinant, Standard Grade |
|
9251-25 |
Biovision |
|
EUR 294 |
Proteinase K, Recombinant, Standard Grade |
|
9251-5 |
Biovision |
|
EUR 120 |
 Lyophilized recombinant standard |
|
ST0000-4 |
BosterBio |
4ng/vial |
EUR 172 |
 Antibody (Biotin)) Carbohydrate Antigen 72-4 (CA72-4) Antibody (Biotin) |
|
20-abx272556 |
Abbexa |
-
EUR 425.00
-
EUR 230.00
-
EUR 1191.00
-
EUR 578.00
-
EUR 328.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
|
) ExoStd? Lyophilized Exosome Standard (30 µg, Human Plasma, 4 vials) |
|
M1040-4 |
Biovision |
|
EUR 909 |
) ExoStd? Lyophilized Exosome Standard (100 µg, Human Plasma, 4 vials) |
|
M1041-4 |
Biovision |
|
EUR 1137 |
) ExoStd? Lyophilized Exosome Standard (30 µg, Human Serum, 4 vials) |
|
M1042-4 |
Biovision |
|
EUR 909 |
) ExoStd? Lyophilized Exosome Standard (100 µg, Human Serum, 4 vials) |
|
M1043-4 |
Biovision |
|
EUR 1132 |
) ExoStd? Lyophilized Exosome Standard (30 µg, Human Urine, 4 vials) |
|
M1044-4 |
Biovision |
|
EUR 909 |
) ExoStd? Lyophilized Exosome Standard (100 µg, Human Urine, 4 vials) |
|
M1045-4 |
Biovision |
|
EUR 1137 |
) ExoStd? Lyophilized Exosome Standard (30 µg, Human Saliva, 4 vials) |
|
M1046-4 |
Biovision |
|
EUR 914 |
) ExoStd? Lyophilized Exosome Standard (100 µg, Human Saliva, 4 vials) |
|
M1047-4 |
Biovision |
|
EUR 1137 |
) ExoStd? Lyophilized Exosome Standard (30 µg, U87 MG, 4 vials) |
|
M1054-4 |
Biovision |
|
EUR 914 |
) ExoStd? Lyophilized Exosome Standard (100 µg, U87 MG, 4 vials) |
|
M1055-4 |
Biovision |
|
EUR 1142 |
) ExoStd? Lyophilized Exosome Standard (30 µg, COLO1 cell line, 4 vials) |
|
M1048-4 |
Biovision |
|
EUR 914 |
) ExoStd? Lyophilized Exosome Standard (100 µg, COLO1 cell line, 4 vials) |
|
M1049-4 |
Biovision |
|
EUR 1142 |
) ExoStd? Lyophilized Exosome Standard (30 µg, MM1 cell line, 4 vials) |
|
M1050-4 |
Biovision |
|
EUR 914 |
) ExoStd? Lyophilized Exosome Standard (100 µg, MM1 cell line, 4 vials) |
|
M1051-4 |
Biovision |
|
EUR 1142 |
) ExoStd? Lyophilized Exosome Standard (30 µg, BLCL21 cell line, 4 vials) |
|
M1052-4 |
Biovision |
|
EUR 914 |
) ExoStd? Lyophilized Exosome Standard (100 µg, BLCL21 cell line, 4 vials) |
|
M1053-4 |
Biovision |
|
EUR 1142 |
) ExoStd? Lyophilized Exosome Standard (30 µg, HCT116 cell line, 4 vials) |
|
M1058-4 |
Biovision |
|
EUR 914 |
) ExoStd? Lyophilized Exosome Standard (100 µg, HCT116 cell line, 4 vials) |
|
M1059-4 |
Biovision |
|
EUR 1142 |
) ExoStd? Lyophilized Exosome Standard (30 µg, PC3 cell line, 4 vials) |
|
M1060-4 |
Biovision |
|
EUR 914 |
) ExoStd? Lyophilized Exosome Standard (100 µg, PC3 cell line, 4 vials) |
|
M1061-4 |
Biovision |
|
EUR 1142 |
) ExoStd? Lyophilized Exosome Standard (30 µg, DAUD1 cell line, 4 vials) |
|
M1064-4 |
Biovision |
|
EUR 914 |
) ExoStd? Lyophilized Exosome Standard (100 µg, DAUD1 cell line, 4 vials) |
|
M1065-4 |
Biovision |
|
EUR 1142 |
) ExoStd? Lyophilized Exosome Standard (30 µg, A549 cell line, 4 vials) |
|
M1066-4 |
Biovision |
|
EUR 914 |
) ExoStd? Lyophilized Exosome Standard (100 µg, A549 cell line, 4 vials) |
|
M1067-4 |
Biovision |
|
EUR 1142 |
) ExoStd? Lyophilized Exosome Standard (30 µg, B16F10 cell line, 4 vials) |
|
M1070-4 |
Biovision |
|
EUR 914 |
) ExoStd? Lyophilized Exosome Standard (100 µg, B16F10 cell line, 4 vials) |
|
M1071-4 |
Biovision |
|
EUR 1142 |
 Polystyrene Particle Size Standard |
|
PPS-4 |
Spherotech |
mL |
EUR 131 |
|
Description: Please reffer to the technical data sheet for more detail information for this item. Our dedicated team would be happy to assist you via live chat, email or phone. |
 ELISA kit) Human carbonhydrate antigen 72-4 (CA72-4) ELISA kit |
|
CSB-E09411h-24T |
Cusabio |
1 plate of 24 wells |
EUR 165 |
|
|
|
Description: Quantitativesandwich ELISA kit for measuring Human carbonhydrate antigen 72-4 (CA72-4) in samples from serum, plasma, cell culture supernates, tissue homogenates. A new trial version of the kit, which allows you to test the kit in your application at a reasonable price. |
Human carbonhydrate antigen 72-4 (CA72-4) ELISA kit |
|
1-CSB-E09411h |
Cusabio |
-
EUR 900.00
-
EUR 5476.00
-
EUR 2900.00
|
- 1 plate of 96 wells
- 10 plates of 96 wells each
- 5 plates of 96 wells each
|
|
|
|
Description: Quantitativesandwich ELISA kit for measuring Human carbonhydrate antigen 72-4 (CA72-4) in samples from serum, plasma, cell culture supernates, tissue homogenates. Now available in a cost efficient pack of 5 plates of 96 wells each, conveniently packed along with the other reagents in 5 separate kits. |
Human Carbohydrate Antigen 72-4 (CA72-4) ELISA Kit |
|
abx572074-96tests |
Abbexa |
96 tests |
EUR 786 |
|
|
 Cancer Antigen 242 Antigen |
|
VAng-Cr3876-10kU |
Creative Biolabs |
10 kU |
EUR 421 |
|
Description: Cancer Antigen 242 Antigen, Host/Source: Metastatic Liver. The purity is detected by gel filtration. |
 Cancer Antigen 50 Antigen |
|
VAng-Cr3877-50kU |
Creative Biolabs |
50 kU |
EUR 5535 |
|
Description: Cancer Antigen 50 Antigen, Host/Source: Human Cell Culture. It is tested negative for HBsAg, antibodies to HCV and HIV 1/2. |
) ExoStd? Lyophilized Exosome Standard (30 µg, BPH-1 cell line, 4 vials) |
|
M1062-4 |
Biovision |
|
EUR 914 |
) ExoStd? Lyophilized Exosome Standard (100 µg, BPH-1 cell line, 4 vials) |
|
M1063-4 |
Biovision |
|
EUR 1142 |
) ExoStd? Lyophilized Exosome Standard (30 µg, K-562 cell line, 4 vials) |
|
M1068-4 |
Biovision |
|
EUR 914 |
) ExoStd? Lyophilized Exosome Standard (100 µg, K-562 cell line, 4 vials) |
|
M1069-4 |
Biovision |
|
EUR 1142 |
) ExoStd? Lyophilized Exosome Standard (30 µg, SK-N-SH cell line, 4 vials) |
|
M1056-4 |
Biovision |
|
EUR 914 |
) ExoStd? Lyophilized Exosome Standard (100 µg, SK-N-SH cell line, 4 vials) |
|
M1057-4 |
Biovision |
|
EUR 1142 |
) Inactivated RuV Grade 4 Antigen (Strain HPV-77) |
|
VAng-0638Lsx-inquire |
Creative Biolabs |
inquire |
Ask for price |
|
Description: RuV (Strain HPV-77) Grade 4 antigen, inactivated by UV and verified by infectivity testing. 0.50 mg/mL. |
) Vitamin A Reference Standard (USP grade powder) |
|
51R-U716002 |
Fitzgerald |
10 pack |
EUR 516 |
|
Description: Vitamin A Reference Standard (USP grade powder) chemical reference substance |
 CEA Antigen Grade Protein |
|
abx060976-05mg |
Abbexa |
0.5 mg |
EUR 968 |
|
|
CEA Antigen Grade Protein |
|
abx060977-1mg |
Abbexa |
1 mg |
EUR 1692 |
|
|
 Prostate Specific Antigen Std Grade Antigen |
|
VAng-Cr3891-1mg |
Creative Biolabs |
1 mg |
EUR 504 |
|
Description: Prostate Specific Antigen Std Grade Antigen, Host/Source: Human Seminal Fluid. The purity is detected by salt precipitation. |
ELISA Kit) Human colon cancer-specific antigen-4(CCSA-4)ELISA Kit |
|
GA-E1681HM-48T |
GenAsia Biotech |
48T |
EUR 289 |
Human colon cancer-specific antigen-4(CCSA-4)ELISA Kit |
|
GA-E1681HM-96T |
GenAsia Biotech |
96T |
EUR 466 |
 Human colon cancer-specific antigen-4,CCSA-4 ELISA kit |
|
201-12-1665 |
SunredBio |
96 tests |
EUR 440 |
|
|
|
Description: A quantitative ELISA kit for measuring Human in samples from biological fluids. |
 ELISA Kit) Pig Colon Cancer Specific Antigen-4 (CCSA-4) ELISA Kit |
|
abx360753-96tests |
Abbexa |
96 tests |
EUR 825 |
|
|
 ELISA Kit) Rabbit Colon Cancer Specific Antigen-4 (CCSA-4) ELISA Kit |
|
abx363654-96tests |
Abbexa |
96 tests |
EUR 825 |
|
|
 ELISA Kit) Human Colon Cancer Specific Antigen 4 (CCSA-4) ELISA Kit |
|
abx354340-96tests |
Abbexa |
96 tests |
EUR 707 |
|
|
 ELISA Kit) Chicken Colon Cancer Specific Antigen-4 (CCSA-4) ELISA Kit |
|
abx355731-96tests |
Abbexa |
96 tests |
EUR 825 |
|
|
 ELISA Kit) Monkey Colon Cancer Specific Antigen-4 (CCSA-4) ELISA Kit |
|
abx358784-96tests |
Abbexa |
96 tests |
EUR 825 |
|
|
Human colon cancer-specific antigen-4(CCSA-4)ELISA Kit |
|
QY-E03945 |
Qayee Biotechnology |
96T |
EUR 361 |
 Standard) Exo-Check Exosome Antibody Array (Neuro) Standard |
|
EXORAY500A-4 |
SBI |
4 arrays |
EUR 690 |
 ELISA test) TA(Anti-Trophoblast Membrane Antibody IgM) ELISA test |
|
72 |
Biobase |
96T/Box |
Ask for price |
|
|
|
Description: ELISA based test for quantitative detection of TA(Anti-Trophoblast Membrane Antibody IgM) |
 Standard grade heat shock BSA powder, pH 7 |
|
BAH62-0050 |
Equitech |
50gm |
EUR 257.4 |
|
|
Standard grade heat shock BSA powder, pH 7 |
|
BAH62-0100 |
Equitech |
100gm |
EUR 323.7 |
|
|
Standard grade heat shock BSA powder, pH 7 |
|
BAH62-0500 |
Equitech |
500gm |
EUR 426.4 |
|
|
Standard grade heat shock BSA powder, pH 7 |
|
BAH62-1000 |
Equitech |
1KG |
Ask for price |
|
|
Standard grade heat shock BSA powder, pH 7 |
|
BAH62-10000 |
Equitech |
10KG |
Ask for price |
|
|
 Standard grade heat shock BSA powder, pH 5.2 |
|
BAH63-0050 |
Equitech |
50gm |
EUR 257.4 |
|
|
Standard grade heat shock BSA powder, pH 5.2 |
|
BAH63-0100 |
Equitech |
100gm |
EUR 323.7 |
|
|
Standard grade heat shock BSA powder, pH 5.2 |
|
BAH63-0500 |
Equitech |
500gm |
EUR 426.4 |
|
|
Standard grade heat shock BSA powder, pH 5.2 |
|
BAH63-1000 |
Equitech |
1KG |
Ask for price |
|
|
Standard grade heat shock BSA powder, pH 5.2 |
|
BAH63-10000 |
Equitech |
10KG |
Ask for price |
|
|
) Cancer Antigen CEA Antigen (Human Fluids) |
|
VAng-Wyb8644-inquire |
Creative Biolabs |
inquire |
Ask for price |
|
Description: Carcinoembryonic Antigen, Calibrator Grade, Cancer antigen from Human Fluids, 1.13 mg/mL. |
) Cancer Antigen 125 Antigen (Human Adenocarcinoma) |
|
VAng-Cr3868-10kU |
Creative Biolabs |
10 kU |
EUR 421 |
|
Description: Cancer Antigen 125 Antigen, Host/Source: Human Adenocarcinoma. The purity is detected by salt extraction and chromatography. |
) Cancer Antigen 125 Antigen (Ascites Fluid) |
|
VAng-Cr3870-10kU |
Creative Biolabs |
10 kU |
EUR 944 |
|
Description: Cancer Antigen 125 Antigen, Host/Source: Ascites Fluid. The purity is ≥ 95% by SDS-PAGE. |
 ODN M362-Type C human/murine TLR9 agonist-antigen grade-antigen grade |
|
ODNM362-1 |
Alpha Diagnostics |
1 mg |
EUR 651 |
ODN M362-Type C human/murine TLR9 agonist-antigen grade-antigen grade |
|
ODNM362-5 |
Alpha Diagnostics |
5 mg |
EUR 1991 |
 Protein) Human Cancer Antigen CA125 (Ovarian Cancer) Protein |
|
abx061590-100kU |
Abbexa |
100 kU |
EUR 1205 |
|
|
) ELISA kit for Human Colon cancer-specific antigen-4 (CCSA-4) |
|
KTE62592-48T |
Abbkine |
48T |
EUR 332 |
|
|
|
Description: Quantitative sandwich ELISA for measuring Human Colon cancer-specific antigen-4 (CCSA-4) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids. |
ELISA kit for Human Colon cancer-specific antigen-4 (CCSA-4) |
|
KTE62592-5platesof96wells |
Abbkine |
5 plates of 96 wells |
EUR 2115 |
|
|
|
Description: Quantitative sandwich ELISA for measuring Human Colon cancer-specific antigen-4 (CCSA-4) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids. |
ELISA kit for Human Colon cancer-specific antigen-4 (CCSA-4) |
|
KTE62592-96T |
Abbkine |
96T |
EUR 539 |
|
|
|
Description: Quantitative sandwich ELISA for measuring Human Colon cancer-specific antigen-4 (CCSA-4) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids. |
) ELISA kit for Human CCSA-4 (Colon Cancer Specific Antigen-4) |
|
E-EL-H0795 |
Elabscience Biotech |
1 plate of 96 wells |
EUR 534 |
|
|
|
Description: A sandwich ELISA kit for quantitative measurement of Human CCSA-4 (Colon Cancer Specific Antigen-4) in samples from Serum, Plasma, Cell supernatant |
) Recombinant CEA Protein (Antigen Grade) |
|
VAng-Wyb8647-inquire |
Creative Biolabs |
inquire |
Ask for price |
|
Description: Carcinoembryonic Antigen, Antigen Grade, recombinant protein from Cell Culture, 3.71 mg/mL. |
 Antigen Grade) Imidazoquinoline (TLR7 Agonist) Antigen Grade |
|
VAdv-Ly0018-25mg |
Creative Biolabs |
25 mg |
EUR 3610 |
|
Description: Imidazoquinoline, a TLR7 agonist vaccine adjuvant. |
Imidazoquinoline (TLR7 Agonist) Antigen Grade |
|
VAdv-Ly0018-5mg |
Creative Biolabs |
5 mg |
EUR 861 |
|
Description: Imidazoquinoline, a TLR7 agonist vaccine adjuvant. |
 Ck-Mm Antigen Grade Protein |
|
abx060710-1mg |
Abbexa |
1 mg |
EUR 648 |
|
|
 Human AFP Antigen Grade Protein |
|
abx060957-1mg |
Abbexa |
1 mg |
EUR 926 |
|
|
Human AFP Antigen Grade Protein |
|
abx060958-1mg |
Abbexa |
1 mg |
EUR 1316 |
|
|
Human AFP Antigen Grade Protein |
|
abx060959-1mg |
Abbexa |
1 mg |
EUR 996 |
|
|
 Human CA125 Antigen Grade Protein |
|
abx060960-50kU |
Abbexa |
50 kU |
EUR 801 |
|
|
 Inactivated MeV Grade 2 Antigen |
|
VAng-Lsx0384-inquire |
Creative Biolabs |
inquire |
Ask for price |
|
Description: Measles Grade 2, native virus. |
 Inactivated MuV Grade 2 Antigen |
|
VAng-Lsx0409-inquire |
Creative Biolabs |
inquire |
Ask for price |
|
Description: MuV Grade 2, native virus. |
 Inactivated MuV Grade 3 Antigen |
|
VAng-Lsx0411-inquire |
Creative Biolabs |
inquire |
Ask for price |
|
Description: MuV grade 3, native protein. |
 Inactivated ADV Grade 2 Antigen |
|
VAng-Lsx0003-1mL |
Creative Biolabs |
1 mL |
EUR 998 |
|
Description: ADV Grade 2, natural antigen. |
 Inactivated CMV Grade 2 Antigen |
|
VAng-Lsx0037-1mg |
Creative Biolabs |
1 mg |
EUR 2027 |
|
Description: CMV Grade 2, natural protein. |
 Inactivated CMV Grade 3 Antigen |
|
VAng-Lsx0038-1mg |
Creative Biolabs |
1 mg |
EUR 2086 |
|
Description: CMV Grade 3, natural protein. |
 Inactivated VZV Grade 2 Antigen |
|
VAng-Lsx0555-inquire |
Creative Biolabs |
inquire |
Ask for price |
|
Description: VZV Grade 2, native virus. |
 Inactivated Rotavirus Grade 3 Antigen |
|
VAng-Lsx0469-inquire |
Creative Biolabs |
inquire |
Ask for price |
|
Description: Rotavirus Grade 3, native virus. |
 Inactivated RuV Grade 2 Antigen |
|
VAng-Lsx0475-inquire |
Creative Biolabs |
inquire |
Ask for price |
|
Description: RuV Grade 2, natural protein. |
 Inactivated RuV Grade 3 Antigen |
|
VAng-Lsx0476-1mL |
Creative Biolabs |
1 mL |
EUR 395 |
|
Description: RuV Grade 3, natural protein. |
 Human Cancer OptiTDS1: Tissue Dissociation System |
|
4-28024 |
CHI Scientific |
1 Kit |
Ask for price |
 Human Cancer OptiTDS2: Tissue Dissociation System |
|
4-28025 |
CHI Scientific |
1 Kit |
Ask for price |
 Human Cancer OptiTDS3: Tissue Dissociation System |
|
4-28026 |
CHI Scientific |
1 Kit |
Ask for price |
 Human Cancer OptiTDS4: Tissue Dissociation System |
|
4-28027 |
CHI Scientific |
1 Kit |
Ask for price |
 Human Cancer OptiTDS5: Tissue Dissociation System |
|
4-28028 |
CHI Scientific |
1 Kit |
Ask for price |
 Human Cancer OptiTDS6: Tissue Dissociation System |
|
4-28029 |
CHI Scientific |
1 Kit |
Ask for price |
 Human Cancer OptiTDS7: Tissue Dissociation System |
|
4-28030 |
CHI Scientific |
1 Kit |
Ask for price |
 Human Cancer OptiTDS8: Tissue Dissociation System |
|
4-28031 |
CHI Scientific |
1 Kit |
Ask for price |
 Human Cancer OptiTDS9: Tissue Dissociation System |
|
4-28032 |
CHI Scientific |
1 Kit |
Ask for price |
 Human Cancer OptiTDS10: Tissue Dissociation System |
|
4-28033 |
CHI Scientific |
1 Kit |
Ask for price |
 Human Cancer OptiTDS11: Tissue Dissociation System |
|
4-28034 |
CHI Scientific |
1 Kit |
Ask for price |
 Human Cancer OptiTDS12: Tissue Dissociation System |
|
4-28035 |
CHI Scientific |
1 Kit |
Ask for price |
 Human Cancer OptiTDS13: Tissue Dissociation System |
|
4-28036 |
CHI Scientific |
1 Kit |
Ask for price |
 Human Cancer OptiTDS14: Tissue Dissociation System |
|
4-28037 |
CHI Scientific |
1 Kit |
Ask for price |
 Human Cancer OptiTDS15: Tissue Dissociation System |
|
4-28038 |
CHI Scientific |
1 Kit |
Ask for price |
 Human Cancer OptiTDS16: Tissue Dissociation System |
|
4-28039 |
CHI Scientific |
1 Kit |
Ask for price |
 Human Cancer OptiTDS18: Tissue Dissociation System |
|
4-28041 |
CHI Scientific |
1 Kit |
Ask for price |
 Human Cancer OptiTDS19: Tissue Dissociation System |
|
4-28042 |
CHI Scientific |
1 Kit |
Ask for price |
 CA 72-4 protein |
|
30-1069 |
Fitzgerald |
1 kU |
EUR 124 |
|
Description: Purified native Human CA 72-4 protein |
CA 72-4 protein |
|
30-AC23 |
Fitzgerald |
50 KU |
EUR 314 |
|
Description: Purified native Human CA 72-4 protein |
CA 72-4 protein |
|
30-AC24 |
Fitzgerald |
50 KU |
EUR 390 |
|
Description: Purified native Human CA 72-4 protein |
CA 72-4 protein |
|
30C-CP1065S |
Fitzgerald |
25 KU |
EUR 327 |
|
Description: Highly purified Human CA 72-4 protein |
Sensitization results of quick FUS pictures with cavitation (FUS-Cav) or with out cavitation (FUS) to RT or HT have been evaluated. FUS-Cav considerably will increase the sensitivity of most cancers cells to RT and HT by lowering long-term clonogenic survival, short-term cell metabolic exercise, cell invasion, and induction of sonoporation. Our outcomes demonstrated that quick FUS remedy with cavitation has good potential to sensitize most cancers cells to RT and HT non-invasively.
